Sector in which the organization works:
Short description of the organization and its work to control and eliminate NTDs
Gilead Sciences is a biopharmaceutical company that discovers and develops innovative medicines for life-threatening diseases, including HIV/AIDS, hepatitis B and visceral leishmaniasis. Gilead makes it a priority to increase access to these medicines for people who can benefit from them, regardless of where they live or their ability to pay.
Experts from the World Health Organization (WHO) and other public health institutions around the world recommend Gilead's antifungal medicine AmBisome® (amphotericin B liposome for injection) as a first-line treatment against VL in many parts of the world.
We work closely with WHO and non-governmental organizations to provide AmBisome at a preferential price for the treatment of leishmaniasis, and we supply the treatment at not-for-profit pricing to projects addressing VL in India, where the disease is endemic.
Gilead has supported clinical research studies aimed at identifying the best treatment course for VL, and has donated AmBisome to support clinical studies assessing combination therapies and the cost-effectiveness of multiple VL treatment interventions. In December of 2011, Gilead signed a partnership agreement with WHO to donate 445,000 vials of AmBisome over five years. This donation, which is equivalent to $8 million in product if sold at the no-profit access price, will be used to treat more than 50,000 patients in resource-limited countries.
Through our collaborations we are also working to make AmBisome available for other serious medical conditions in Bangladesh, Ethiopia, India, Kenya, Nepal and Sudan - countries where the prevalence of serious fungal infections is high, particularly among HIV-infected immune-compromised patients.
Gilead Sciences is one of the 20 original endorsers of the London Declaration